Therapeutics News and Research

RSS

Bayer's Adalat XL product and Mylan's nifedipine extended release 60 mg not bioequivalent: Study

Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.

25 May 2010

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

24 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

Researchers look for new ways of targeting Alzheimer's disease

The Alzheimer's Association released a report on Wednesday, May 19, predicting that the cost of Alzheimer's disease over the next 40 years would reach $20 trillion if newer treatments are not on the horizon.

24 May 2010

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $21.0 million of shares of its Series 5 Preferred Stock in a registered offering to three institutional investors (collectively, the "Initial Purchasers"). Each share of Series 5 Preferred Stock is convertible at the option of the holder, at any time during its existence, into 2,500 shares of common stock at a conversion price of $0.40 per share of common stock, for a total of 52,500,000 shares of common stock.

24 May 2010

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it will be presenting results from its clinical trial of ICT-107 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

21 May 2010

Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.

21 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Pluristem to highlight potential of PLX-PAD cell therapy for critical limb ischemia at 16th ISCT

Pluristem Therapeutics Inc. today announced that its off-the-shelf placenta-derived cell therapies will be the focus of presentations at upcoming investor and medical conferences.

21 May 2010

Influenza antiviral drugs not hoarded during recent H1N1 flu season, says Prime Therapeutics

Despite concerns from public health officials, influenza antiviral drugs were not hoarded during the recent H1N1 flu season, according to a new analysis presented recently at the Academy of Managed Care Pharmacy's 22nd Annual Meeting in San Diego by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.

21 May 2010

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Ill. from June 4 through June 8, 2010.

21 May 2010

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.

21 May 2010

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

Amsterdam Molecular Therapeutics a world leader in gene therapy, today reported positive preclinical data from a study using an AAV gene therapy product to lower cholesterol.

21 May 2010

McMaster University announces affiliation agreement with Centre for Drug Research and Development

McMaster University and the Centre for Drug Research and Development (CDRD) today announced that McMaster University has signed an affiliation agreement with CDRD that will facilitate seamless collaboration by and between McMaster's academic investigators and the industry experienced drug development professionals at CDRD.

21 May 2010

NIH Director to brief U.S. Senate on ways to leverage investments in medical research

National Institutes of Health (NIH) Director Francis S. Collins, M.D., Ph.D., will lead a briefing on Capitol Hill Thursday, May 20, to discuss how funding for medical research at the NIH can be used more quickly to create new therapies for patients and save lives.

20 May 2010

Trius awarded new DTRA contract for developing novel antibiotics against gram-negative bacterial pathogens

Trius Therapeutics, Inc. today announced that it has been awarded a new four and a half year contract from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, for the development of novel antibiotics directed against gram-negative bacterial pathogens. Trius may receive up to $29.5 million in support of development efforts under the new DTRA contract, which is funded as part of DTRA's Transformational Medical Technologies Initiative (TMTI).

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.

20 May 2010

Therapeutics News and Research

Bayer's Adalat XL product and Mylan's nifedipine extended release 60 mg not bioequivalent: Study

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Researchers look for new ways of targeting Alzheimer's disease

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

New therapy program serves as foundation for ongoing clinical development

Pluristem to highlight potential of PLX-PAD cell therapy for critical limb ischemia at 16th ISCT

Influenza antiviral drugs not hoarded during recent H1N1 flu season, says Prime Therapeutics

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

McMaster University announces affiliation agreement with Centre for Drug Research and Development

NIH Director to brief U.S. Senate on ways to leverage investments in medical research

Trius awarded new DTRA contract for developing novel antibiotics against gram-negative bacterial pathogens

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News